Daily low dose of tadalafil improves pain and frequency in bladder pain syndrome/interstitial cystitis patients

被引:3
作者
Abreu-Mendes, Pedro [1 ,2 ,3 ,4 ]
Dias, Nuno [1 ,2 ,3 ]
Simaes, Jose [3 ]
Dinis, Paulo [1 ,2 ,3 ]
Cruz, Francisco [1 ,2 ,3 ,4 ]
Pinto, Rui [1 ,2 ,3 ,4 ]
机构
[1] Ctr Hosp, Dept Urol, Porto, Portugal
[2] Univ Sao Joao, Porto, Portugal
[3] Univ Porto, Dept Urol, Fac Med, Porto, Portugal
[4] Univ Porto, Inst Inovat Healt I3S, Porto, Portugal
来源
TURKISH JOURNAL OF UROLOGY | 2022年 / 48卷 / 01期
关键词
Cystitis; drug therapy [E02.319; interstitial [C12.777.829.495.500; phosphodiesterase 5 inhibitors [D27.505.519.389.735.500; tadalafil [D03.633.100.473.155.500; QUALITY-OF-LIFE; INTERSTITIAL CYSTITIS; NITRIC-OXIDE; SILDENAFIL; INHIBITORS; PREVALENCE; ANALGESIA; SYMPTOMS; PATHWAY; RAT;
D O I
10.5152/tud.2022.21292
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: Bladder pain syndrome/interstitial cystitis (BPS/IC) is a chronic disease, with consequent high morbidity. Increasing evidence suggests that bladder afferent hyperexcitability, through neurogenic bladder inflammation and urothelial dysfunction, plays a key role in the pathophysiology of BPS/IC. The rationale of using phosphodiesterase type 5 inhibitors (PDE5i) would be to decrease bladder afferent hyperactivity. Detrusor relaxation, improvement of microcirculation, and a decrease in adrenergic nociceptive overactivity would be other effects in bladder tissue. We aimed to evaluate the efficacy, tolerability, and safety of a daily low dose of 5mg tadalafil in refractory BPS/IC patients. Material and methods: A total of 14 refractory BPS/IC female patients, previously evaluated with a physical examination, bladder diary, bladder-pain related visual analogue score, O'Leary-Sant Scores (OSS) for symptoms and problems, and quality of life (QoL) question from International Prostate Symptom Score, were treated with 5mg of tadalafil, for 3months. Re-evaluations occurred at 4 and 12weeks. Adverse events were assessed and recorded. Results: Urinary frequency, OSS, and QoL were significantly improved at 1-month follow-up (10 6 2.5, 21.9 6 4.1, and 4 6 1.5, respectively, P < .05). Pain intensity and volume voided were significantly improved at a 3-month follow-up (3.5 6 2 and 266.7 6 60.5, P < .05). Patients referred to urinary frequency as the most important parameter improved at 4weeks, and pain at 3months. No differences between ulcerated and nonulcerated patients were observed. Two patients dropped out due to unsatisfactory results and two due to persistent headache and/or tachycardia, but both events were resolved after discontinuing the drug. Conclusion: Daily low-dose tadalafil is an easy, well-tolerated, and effective treatment for refractory BPS/IC in women.
引用
收藏
页码:82 / 87
页数:6
相关论文
共 50 条
  • [41] Management of Interstitial Cystitis/Bladder Pain Syndrome A Urology Perspective
    Quillin, Renee B.
    Erickson, Deborah R.
    UROLOGIC CLINICS OF NORTH AMERICA, 2012, 39 (03) : 389 - +
  • [42] Microbiome profiling inpatients with Bladder Pain Syndrome/Interstitial cystitis
    Elferink, Puck Oude
    Marand, Aida Javan Balegh
    Heesakkers, John
    van den Munckhof, Ellen
    Knetsch, Wilco
    Martens, Frank
    Rahnama'i, Mohammad Sajjad
    Janssen, Dick
    CONTINENCE, 2025, 14
  • [43] A cohort study of interstitial cystitis/bladder pain syndrome and hysterectomy
    Lee, Ming-Huei
    Chang, Kun-Min
    Wu, Shang-Liang
    Lin, Hsuan-Hung
    Lin, Hsiu-Ying
    Wu, Huei-Ching
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2016, 27 (09) : 1401 - 1407
  • [44] Potassium sensitivity test predicts hydrodistention efficacy in patients with bladder pain syndrome/interstitial cystitis
    Gulpinar, Omer
    Esen, Baris
    Akpinar, Cagri
    Baklaci, Utku
    Gokce, Mehmet Ilker
    Suer, Evren
    Beduk, Yasar
    TURKISH JOURNAL OF UROLOGY, 2020, 46 (03): : 231 - 235
  • [45] Understanding pain and coping in women with interstitial cystitis/bladder pain syndrome
    Katz, Laura
    Tripp, Dean A.
    Carr, Lesley K.
    Mayer, Robert
    Moldwin, Robert M.
    Nickel, J. Curtis
    BJU INTERNATIONAL, 2017, 120 (02) : 286 - 292
  • [46] Interventional Pain Management in the Treatment of Interstitial Cystitis/Bladder Pain Syndrome
    Kalajian, Tyler
    Drerup, Brenden
    Drerup, Jennifer
    Burke, Martin
    Selassie, Meron
    CURRENT BLADDER DYSFUNCTION REPORTS, 2025, 20 (01) : 9 - 9
  • [47] Bladder afferent hyperexcitability in bladder pain syndrome/interstitial cystitis
    Yoshimura, Naoki
    Oguchi, Tomohiko
    Yokoyama, Hitoshi
    Funahashi, Yasuhito
    Yoshikawa, Satoru
    Sugino, Yoshio
    Kawamorita, Naoki
    Kashyap, Mahendra P.
    Chancellor, Michael B.
    Tyagi, Pradeep
    Ogawa, Teruyuki
    INTERNATIONAL JOURNAL OF UROLOGY, 2014, 21 : 18 - 25
  • [48] Pathophysiology, assessment, and treatment of overactive bladder symptoms in patients with interstitial cystitis/bladder pain syndrome
    Dobberfuhl, Amy D.
    NEUROUROLOGY AND URODYNAMICS, 2022, 41 (08) : 1958 - 1966
  • [49] Dietary Consumption Triggers in Interstitial Cystitis/Bladder Pain Syndrome Patients
    Bassaly, Renee
    Downes, Katheryne
    Hart, Stuart
    FEMALE PELVIC MEDICINE AND RECONSTRUCTIVE SURGERY, 2011, 17 (01): : 36 - 39
  • [50] Status of International Consensus on Interstitial Cystitis/Bladder Pain Syndrome/Painful Bladder Syndrome: 2008 Snapshot
    Hanno, Philip
    Dmochowski, Roger
    NEUROUROLOGY AND URODYNAMICS, 2009, 28 (04) : 274 - 286